LL-37: The Human Host Defense Peptide — Research Review

LL-37 is the only human cathelicidin, processed from the C-terminus of the hCAP18 precursor protein. Despite its small size — 37 amino acids — it occupies a unique interface between innate immunity, inflammation, wound repair, and antimicrobial defense. Unlike classical AMPs defined purely by membrane lysis, LL-37 operates across multiple receptor systems, producing both direct antimicrobial effects and complex immunomodulatory signaling that shapes downstream adaptive immunity. This dual character makes it a compelling research target in infectious disease, wound biology, dermatology, and tumor immunology.

Origin and Processing: hCAP18 and the CAMP Gene

LL-37 is encoded by the CAMP (Cathelicidin Antimicrobial Peptide) gene on chromosome 3p21.3. The gene produces hCAP18 — an 18 kDa protein that serves as the proprotein for LL-37. hCAP18 is stored in the specific granules of neutrophils, as well as mast cells, NK cells, and various epithelial cell types (skin keratinocytes, lung epithelium, GI mucosa, urogenital tract).

Upon activation — via pathogen recognition, protease release, or cytokine stimulation — hCAP18 is cleaved by serine proteases (primarily proteinase-3 in neutrophils, kallikreins in epithelial cells) to release the 37-aa C-terminal peptide. The designation 'LL-37' derives from its two N-terminal leucines and its 37-residue length. An amphipathic alpha-helix forms between residues 2-31, with hydrophobic residues clustered on one face and cationic lysine/arginine on the other — the canonical structural motif that drives both membrane disruption and receptor interactions.

Mechanism 1: Membrane Disruption — Direct Antimicrobial Activity

LL-37's antimicrobial mechanism involves electrostatic attraction to negatively charged bacterial membrane components (LPS, lipoteichoic acid, phosphatidylglycerol) followed by amphipathic helix insertion. At physiologically relevant concentrations, LL-37 operates via a carpet/detergent model — peptides accumulate on the outer leaflet, form toroidal pores, and disrupt membrane integrity. This is structurally distinct from the barrel-stave pore formation used by defensins.

• Gram-negative coverage: Escherichia coli (MIC 0.5–4 μg/mL), Pseudomonas aeruginosa (MIC 8–16 μg/mL in planktonic form), Klebsiella pneumoniae, Neisseria gonorrhoeae
• Gram-positive coverage: Staphylococcus aureus (MIC 2–8 μg/mL), Streptococcus pyogenes, Enterococcus faecalis — though activity is lower than gram-negative due to thicker peptidoglycan layer
• Biofilm disruption: LL-37 disrupts established Pseudomonas and Staphylococcus biofilms at sub-MIC concentrations (0.1–1 μg/mL) by interfering with quorum sensing signals (3-oxo-C12-HSL in Pseudomonas) and biofilm matrix degradation
• Antifungal: Activity against Candida albicans (MIC ~8 μg/mL) and Cryptococcus neoformans via membrane disruption and glucan synthase inhibition
• Antiviral: LL-37 disrupts influenza A envelope at 10–50 μg/mL, inhibits RSV attachment via direct virion binding, and reduces HSV-1 plaque formation in vitro

Critically, LL-37 at high concentrations is also cytotoxic to mammalian cells. The selectivity window — antimicrobial activity without host toxicity — is roughly 1–16 μg/mL for most pathogens, while cytotoxicity to human erythrocytes begins at ~64 μg/mL. This therapeutic window has driven interest in LL-37 analogs and truncations (e.g., KR-12, a 12-aa minimal active sequence) that preserve antimicrobial function with reduced cytotoxicity.

Mechanism 2: Immunomodulatory Signaling via FPR2 and TLR4

At concentrations below the antimicrobial threshold, LL-37 functions as a chemokine-like immunomodulator through two major receptor systems:

Formyl Peptide Receptor 2 (FPR2/ALX)

FPR2 is a Gi-coupled GPCR expressed on neutrophils, monocytes, dendritic cells, and epithelial cells. LL-37 binds FPR2 with high affinity (Kd ~10 nM range), triggering: intracellular calcium release, PI3Kgamma/Akt activation, ERK1/2 MAPK signaling, beta-arrestin recruitment leading to receptor internalization, and downstream NF-kappaB modulation (context-dependent: pro- or anti-inflammatory depending on co-stimulatory signals). FPR2 engagement drives neutrophil chemotaxis, monocyte differentiation, and mast cell degranulation at low LL-37 concentrations — establishing LL-37 as a chemoattractant for innate immune cells at infection sites.

TLR4 Modulation

LL-37 has a paradoxical TLR4 relationship. It binds LPS directly and sequesters it, preventing TLR4 engagement — an endotoxin-neutralizing function that attenuates septic hyperinflammation. Simultaneously, LL-37 can act as a TLR4 ligand at higher concentrations in the absence of LPS, inducing MyD88-dependent NFkappaB signaling and pro-inflammatory cytokine output. This dual LPS-neutralization/TLR4-activation role positions LL-37 as a rheostat: protective at moderate concentrations during early infection, potentially inflammatory if chronically overexpressed.

Wound Healing: Keratinocyte Migration and EGFR Transactivation

LL-37 is a potent wound-healing mediator through direct EGFR transactivation. In keratinocytes, FPR2 engagement by LL-37 activates matrix metalloproteinases (MMPs), which shed membrane-bound EGFR ligands (HB-EGF, amphiregulin). The released ligands engage EGFR in an autocrine/paracrine manner, triggering ERK1/2 and Src-kinase signaling that drives:

• Keratinocyte migration into wound edge (scratch assay closure accelerated ~40-60% vs control at 1 mcg/mL LL-37)
• Proliferation of epidermal progenitors via PI3K/Akt
• Re-epithelialization of surgical wounds in porcine skin models (Heilborn 2003, Journal of Investigative Dermatology: LL-37 applied to partial-thickness wounds accelerated re-epithelialization by ~33% at day 4)
• Hyaluronic acid synthesis in dermal fibroblasts via TLR4/CD44 cross-talk
• Collagen I upregulation in fibroblasts at 0.5-2 mcg/mL

LL-37 expression is sharply upregulated at wound edges — driven by TGF-beta1, IL-1beta, and mechanical injury signaling — and the peptide persists in wound fluid for 48-72 hours post-injury. Diabetic wounds show significantly reduced LL-37 expression, which may partly explain impaired re-epithelialization in this population.

Angiogenesis: VEGFR2 Signaling

LL-37 promotes neovascularization via VEGFR2 (KDR/Flk-1) activation in endothelial cells. The mechanism involves FPR2-mediated intracellular signaling that increases VEGF transcription, plus direct VEGFR2 transactivation via the same MMP/ligand-shedding pathway used in EGFR transactivation. Koczulla et al. (2003, JCI) showed that LL-37 induced angiogenesis in a chicken chorioallantoic membrane assay and a murine subcutaneous Matrigel plug model, with vessel density comparable to 100 ng/mL VEGF-A controls. This angiogenic function reinforces LL-37's role as a wound-resolution mediator and has raised interest in tumor biology contexts.

Anti-Inflammatory Paradox and Dose Dependency

The anti-inflammatory properties of LL-37 are well-documented but highly concentration-dependent. At low concentrations (0.1-1 mcg/mL), LL-37 reduces LPS-driven TNF-alpha and IL-6 output in human macrophages by 40-60% via LPS sequestration and FPR2-mediated SOCS3 upregulation. At higher concentrations (>4 mcg/mL), cytokine profiles shift toward pro-inflammatory, with IL-8, IL-6, and MCP-1 induction dominating. This concentration dependence means that in vivo the net inflammatory effect of LL-37 will depend critically on local tissue concentration — acutely high at neutrophil degranulation sites, lower and more immunomodulatory in tissues like skin or mucosa under steady-state conditions.

Reconstitution Notes: Aggregation Risk

LL-37 has a strong tendency to self-aggregate in aqueous solution due to its amphipathic character. This is among the most important handling considerations:

• Reconstitute in 0.01% acetic acid (1 mg/mL) rather than neutral water or PBS — low pH reduces amphipathic helix formation and self-association
• Add dilution buffer (PBS, HBSS, or culture media) fresh immediately before use; avoid extended incubation in physiological salt at room temperature
• Avoid vortexing — gentle inversion only; vortexing accelerates fibril/aggregate formation
• Freeze concentrated stock in 0.01% acetic acid at -20C in single-use aliquots (10-50 mcL); discard after single use for cell work
• Check for aggregation before use: the solution should be clear, not opalescent or particulate; if aggregates form, the preparation cannot be reliably dosed
• Working concentrations below 10 mcg/mL in cell culture media typically remain soluble for the duration of a typical experiment (4-24h)

IP Dosing in Rodent Models

LL-37 is typically administered IP or SC in murine models. Common research protocols from the literature:

• Sepsis models (CLP or LPS-induced): 5-10 mg/kg IP at time of LPS challenge (pre-treatment) or +2h (treatment), reduces serum TNF-alpha/IL-6 by ~50-70% and improves 72h survival in C57BL/6 CLP models (Mookherjee et al., 2009, Journal of Immunology)
• Wound healing (excisional wound): Topical application of 5-50 mcg LL-37 in 20 mcL PBS per wound at day 0 and day 2; harvest at days 3, 5, 7 for histology and re-epithelialization scoring
• Lung infection (intranasal): 50-200 mcg per mouse in 25 mcL PBS x daily x 3-5 days; assess bronchoalveolar lavage cell counts and bacterial CFU
• Angiogenesis (Matrigel plug): 1-5 mcg LL-37 per 500 mcL Matrigel plug SC; assess hemoglobin content (Drabkin assay) and CD31 IHC at day 10
• Cancer immunotherapy: Intratumoral injection 10-50 mcg per day in syngeneic tumor models; monitor tumor growth curve and tumor-infiltrating lymphocyte counts by flow

Research Design Considerations

• Aggregation control: Run a parallel aggregation check (DLS or turbidity at 400 nm) on each preparation batch. Aggregated LL-37 has different receptor binding properties and cannot be assumed equivalent to monomeric peptide.
• Concentration window selection: Pre-validate your concentration range in your cell type with a viability assay (MTS/MTT). Cytotoxic concentrations confound mechanistic readouts.
• Scrambled control: Use a scrambled amino acid sequence of equal length and charge as a specificity control — distinguishes amphipathic helix-dependent vs charge-dependent effects.
• FPR2 receptor antagonist controls: WRW4 (FPR2 antagonist) at 10 mcM should block LL-37-driven chemotaxis, EGFR transactivation, and low-dose immunomodulatory effects; EGFR inhibitor (AG1478) controls for transactivation arm.
• Species caveat: Murine cathelicidins (CRAMP — cathelin-related antimicrobial peptide) and human LL-37 are ~67% similar but not identical. Human LL-37 data cannot be directly extrapolated to murine models without confirmation of FPR2 binding in the target species.
• Endotoxin testing: Because LL-37 is often derived from bacterial expression systems or synthesized with standard resin-based SPPS, rigorously test final preparations with LAL assay. Endotoxin contamination can mimic or antagonize LL-37 immunomodulatory effects via independent TLR4 engagement.

Regulatory Note

LL-37 is sold for research use only (RUO). It is not approved for human therapeutic use in the United States or European Union. This article is intended for scientific research professionals and is not medical advice. Researchers are responsible for compliance with all applicable regulations regarding research peptide use in their jurisdiction.